[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-371458-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-371458-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","incidence-screening-and-management-of-de-novo-malignancies-in-liver-transplant-patients-a-review","Incidence, screening, and management of de novo malignancies in liver transplant patients - A review","","Liver transplantation serves as definitive therapy for end-stage liver disease, acute liver failure, and liver cancer, but chronic immunosuppression elevates long-term risks. De novo malignancies account for a substantial share of deaths among recipients surviving past the early post-transplant period, with non-melanoma skin cancers—especially squamous cell carcinoma—being most common. Patients also face increased incidence of solid organ malignancies and lymphoproliferative disorders relative to the general population. Risk is linked to immunosuppression, alcohol or tobacco exposure, viral infections, and underlying liver disease. Tailored screening, enhanced surveillance for early detection, patient education, and management adjustments to immunosuppressive regimens—potentially including mTOR inhibitors—aim to improve outcomes.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/incidence-screening-and-management-of-de-novo-malignancies-in-liver-transplant-patients-a-review/371458/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/incidence-screening-and-management-of-de-novo-malignancies-in-liver-transplant-patients-a-review/371458.png","ImageObject",300,407,{"name":42,"@type":43},"Connor ","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-28","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What are de novo malignancies after liver transplant and why are they important?","Question",{"text":63,"@type":64},"De novo malignancies are new cancers that develop after liver transplantation. They are a major long-term concern because they account for a significant proportion of deaths among recipients surviving beyond the early post-transplant period.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which cancers are most prevalent among de novo malignancies in liver transplant patients?",{"text":68,"@type":64},"Non-melanoma skin cancers are the most prevalent, particularly squamous cell carcinoma. Other important malignancies include Kaposi's sarcoma and post-transplant lymphoproliferative disorders.",{"name":70,"@type":61,"acceptedAnswer":71},"How should de novo malignancies be screened and managed in liver transplant recipients?",{"text":72,"@type":64},"Effective management combines standard oncologic therapies with adjustments to immunosuppressive regimens. Screening should be tailored, using regular dermatologic exams, targeted screening for high-risk cancers, patient education, and enhanced surveillance to support early detection.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},371458,1790227575,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145},687207022233,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","| W | J | T | World Journal of\u003Cbr>Transplantation |\n| --- | --- | --- | --- |\n\nSubmit a Manuscript: [https://www.f6publishing.com](https://www.f6publishing.com) World J Transplant 2025 September 18; 15(3): 101046  \nDOI: 10.5500/wjt.v15.i3.101046 ISSN 2220-3230 (online)  \nREVIEW  \nIncidence, screening, and management of de novo malignancies in liver transplant patients: A review  \nAnmol Singh, Carol Singh, Armaan Dhaliwal, Navdeep Singh, Vikash Kumar, Aalam Sohal, Jonathan Schneider  \nSpecialty type: Transplantation  \nProvenance and peer review:  \nInvited article; Externally peer reviewed.  \nPeer-review model: Single blind  \nPeer-review report’s classification Scientific Quality: Grade B, Grade C  \nNovelty: Grade B, Grade C  \nCreativity or Innovation: Grade B, Grade C  \nScientific Significance: Grade A, Grade C  \nP-Reviewer: Calderon Martinez E; Zhang YY  \nReceived: September 3, 2024  \nRevised: January 29, 2025  \nAccepted: February 27, 2025  \nPublished online: September 18, 2025  \nProcessing time: 227 Days and 2 Hours  \nAnmol Singh, Department of Medicine, Tristar Centennial Medical Center, Nashville, TN 37203, United States  \nCarol Singh, Department of Medicine, Dayanand Medical College and Hospital, Ludhiana 141001, Punjab, India  \nArmaan Dhaliwal, Division of Hematology and Oncology, Lehigh Valley Health Network, Allentown, PA 18103, United States  \nNavdeep Singh, Department of Medicine, Government Medical College, Amritsar 143001, Punjab, India  \nVikash Kumar, Aalam Sohal, Division of Gastroenterology, Creighton University School of Medicine, Phoenix, AZ 85012, United States  \nJonathan Schneider, Division of Gastroenterology, Tristar Centennial Medical Center, Nashville, TN 37203, United States  \nCorresponding author: Aalam Sohal, Academic Fellow, Division of Gastroenterology, Creighton University School of Medicine, 3216 NE 45th Pl Suite 212, Phoenix, AZ 85012, United [States.](States. aalamsohal@gmail.com)[ aalamsohal@gmail.com](States. aalamsohal@gmail.com)  \nAbstract  \nLiver transplantation (LT) is the definitive treatment for end-stage liver disease, acute liver failure, and liver cancer. Although advancements in surgical techniques, postoperative care, and immunosuppressive therapies have significantly improved outcomes, the long-term use of immunosuppression has increased the risk of complications, including infections, cardiovascular disease, and cancer. Among these, de novo malignancies (DNMs) are a major concern, accounting for 20%-25% of deaths in LT recipients surviving beyond the early post-transplant period. Non-melanoma skin cancers, particularly squamous cell carcinoma are the most prevalent DNMs. Other significant malignancies include Kaposi's sarcoma, post-transplant lymphoproliferative disorders, and various solid organ cancers, including head and neck cancers. Compared to the general population, LT patients face a twofold increase in solid organ malignancies and a 30-fold increase in lymphoproliferative disorders. Risk factors for DNM include chronic immunosuppression, alcohol or tobacco use, viral infections, and underlying liver disease. Emerging evidence emphasizes the importance of tailored cancer screening and  \n WJT  [https://www.wjgnet.com](https://www.wjgnet.com) 1 September 18, 2025  Volume 15  Issue 3   \nSingh A et al. DNMs after LT  \nprevention strategies, including regular dermatological examinations, targeted screenings for high-risk cancers, and patient education on lifestyle modifications. Early detection through enhanced surveillance protocols has been shown to improve outcomes. Management of DNMs involves a combination of standard oncological therapies and adjustments to immunosuppressive regimens, with promising results from the use of mTOR inhibitors in select patients. The review highlights the critical need for ongoing research to refine risk stratification, optimize screening protocols, and improve treatment approaches to mitigate the burden of DNMs in LT recipients. By implementing","cbCaicBeRsfOvHXe","https://ap.wps.com/l/cbCaicBeRsfOvHXe","pdf",1169343,17,"English","# Introduction\n## Abstract\n## Key Words\n## Core Tip\n## Citation","[{\"question\":\"What are de novo malignancies after liver transplant and why are they important?\",\"answer\":\"De novo malignancies are new cancers that develop after liver transplantation. They are a major long-term concern because they account for a significant proportion of deaths among recipients surviving beyond the early post-transplant period.\"},{\"question\":\"Which cancers are most prevalent among de novo malignancies in liver transplant patients?\",\"answer\":\"Non-melanoma skin cancers are the most prevalent, particularly squamous cell carcinoma. Other important malignancies include Kaposi's sarcoma and post-transplant lymphoproliferative disorders.\"},{\"question\":\"How should de novo malignancies be screened and managed in liver transplant recipients?\",\"answer\":\"Effective management combines standard oncologic therapies with adjustments to immunosuppressive regimens. Screening should be tailored, using regular dermatologic exams, targeted screening for high-risk cancers, patient education, and enhanced surveillance to support early detection.\"}]","Incidence, screening, and management of de novo malignancies in liver transplant patients - A review | PDF",1790192120,43]